Safety and efficacy of olanzapine versus perphenazine in patients with schizophrenia: Results of a multicenter, 18-week, double-blind clinical trial;Bezpieczeństwo i skuteczność leczenia olanzapina̧ - W porównaniu z perfenazyna̧ - Chorych na schizofreniȩ. Wyniki 18-tygodniowego badania wieloośrodkowego w warunkach podwójnie ślepej próby

Psychiatria Polska

Volumn 37, Issue 4, 2003, Pages 641-655

  Jarema, Marek ^a   Olajossy, Marcin ^b   Chrzanowski, Włodzimierz ^b   Araszkiewicz, Aleksander ^b   Landowski, Jerzy ^b   Rybakowski, Janusz ^b   Bilikiewicz, Adam ^b   Bomba, Jacek ^b   Dȩbowska, Grazyna ^b  

^a Instytut Psychiatrii i Neurologii III Klinika Psychiatryczna Warszawa   (Poland)

^b NONE

Author keywords

Efficacy; Olanzapine; Perphenazine; Safety; Schizophrenia; Treatment

Indexed keywords

OLANZAPINE; PERPHENAZINE;

ADULT; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PATIENT COMPLIANCE; POLAND; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIMPSON ANGUS SCALE;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PERPHENAZINE; PIRENZEPINE; POLAND; PROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0141886171     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NS, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacol. 1996; 14: 87-96.
2. Moore NA, Calligaro DO, Wong DT, Bymaster FP, Tye NC. The pharmacology of olanzapine, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. 1992; 262: 545-551.
3. Beasley SM, Tollefson G, Tran P. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol. 1996; 14: 111-123.
4. Beasley SM, Tollefson G, Tran P. Efficacy of olanzapine: an overview of pivotal clinical trials. J. Clin. Psychiatr. 1997; 58, supl. 10: 7-12.
5. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schzizophrenia. Biol. Psychiatr. 1999; 45: 403-411.
6. Fulton B, Goa KL. Olanzapine. A review of its pharmacological and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997; 53: 281-298.
7. Gerlach J, Peacock L. New antipsychotics: the present status. Int. Clin. Psychopharmacol. 1995; 10, supl. 3: 39-48.
8. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J. Clin. Psychiatr. 1997; 58, supl. 10: 18-21.
9. Jarema M. Badania kliniczne olanzapiny. Przegla̧d piśmiennictwa. W: Kostowski W, Jarema M., red. Olanzapina, lek przeciwpsychotyczny nowej generacji. Biblioteka Psychiatrii Polskiej, Kraków; 1998; s. 19-27.
10. Kostowski W, Jarema M., red. Olanzapina, lek przeciwpsychotyczny nowejgeneracji. Biblioteka Psychiatrii Polskiej, Kraków; 1998.
11. Tollefson GD, Beasley CM, Tran PV, Street JS, Kruger JA, Tamura RN, Grafeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatr. 1997; 154: 457-465.
12. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine and haloperidol. Am. J. Psychiatry 1997; 154, 9: 1248-1254.
13. Goldstein JM. Atypical antipsychotic drugs: beyond acute psychosis, new directions. Emerging Drugs 1999; 4: 127-151.
14. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J. Clin. Psychiatr. 1996; 57, supl. 11: 53-60.
15. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970; supl. 212: 11-19.
16. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. IV edition. Washington: APA; 1994.
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962; 10: 799-812.
18. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schiz. Bull. 1987; 13: 261-276.
19. Guy W. ECDEU Assessment manual for psychopharmacology, revised. US Department of Health, Education and Welfare. Rockville, MD: NIMH; 1976.
20. Barnes TR. A rating-scale for drug-induced akathisia. Brit. J. Psychiatry 1989; 154: 672-676.
21. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. Acta Psychiatr. Scand. 1987; 76, supl. 334.
22. Beasley SM, Tollefson G, Tran P. Safety of olanzapine. J. Clin. Psychiatr. 1997; 58, supl. 10: 13-17.
23. Gomez JC, Sacristan JA, Hernandez J, Breier A, Carrasco PR, Saiz CA, Carbonell EF. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). J Clin. Psychiatr. 2000; 61:335-343.
24. Tran PV, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J. Clin. Psychiatr. 1997; 58 (5): 11-19.
25. Weiden P. Olanzapine: a new atypical antipsychotic. J. Prac. Psychiatr. Behav. Health 1997; 3: 49-53.
26. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C, Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 1999; 156: 79-87.
27. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr. Scand. 1999; 100: 3-16.
28. Umbricht DSG, Pollack S, Kane JM. Clozapine and weight gain. J. Clin. Psychiatr. 1994; 55, supl. 9: 157-160.
29. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR. Novel antipsychotics: comparison of weight gain liabilities. J. Clin. Psychiatr. 1999; 60: 358-363.
30. Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, Mintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia. Am. J. Psychiatry 2000; 157: 987-993.